Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer

$279,437P50FY2014CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications & trials

Paper 39702422 Paper 39567747 Paper 39546575 Paper 39478111 Paper 39048900 Paper 38947074 Paper 38885312 Paper 38766070 Paper 38709925 Paper 38622115 Paper 38615489 Paper 38458201 Paper 38260436 Paper 38190580 Paper 38167908 Paper 38100350 Paper 38011567 Paper 37980405 Paper 37900827 Paper 37676980 Paper 37399356 Paper 37141550 Paper 37076617 Paper 36951169 Paper 36914658 Paper 36889065 Paper 36817465 Paper 36619972 Paper 36609487 Paper 36463275 Paper 36441774 Paper 36409824 Paper 36352222 Paper 36325581 Paper 36268097 Paper 36223740 Paper 36074155 Paper 36068244 Paper 36048535 Paper 35923923 Paper 35797509 Paper 35766387 Paper 35658506 Paper 35641483 Paper 35617956 Paper 35482127 Paper 35447074 Paper 35446942 Paper 35363308 Paper 35304604 Paper 35304445 Paper 35292783 Paper 35248122 Paper 35149538 Paper 35110417 Paper 35025636 Paper 34853355 Paper 34607954 Paper 34508104 Paper 34388391 Paper 34353349 Paper 34179826 Paper 33997789 Paper 33976133 Paper 33941591 Paper 33891890 Paper 33738458 Paper 33385331 Paper 33293374 Paper 33257427 Paper 33256808 Paper 33138866 Paper 32997991 Paper 32975478 Paper 32939016 Paper 32704543 Paper 32601199 Paper 32576627 Paper 32571778 Paper 32546544 Paper 32416067 Paper 32393766 Paper 32277005 Paper 32249764 Paper 32245699 Paper 32170028 Paper 32067680 Paper 32019858 Paper 31670078 Paper 31462705 Paper 31409614 Paper 31263220 Paper 31061067 Paper 31015319 Paper 30988298 Paper 30962322 Paper 30956894 Paper 30840889 Paper 30795773 Paper 30692147

Abstract

Although HER2-directed therapies are effective in the subset of breast cancers characterized by amplification of the HER2 gene (HER2+), resistance to these therapies remains an important clinical problem and the mechanisms of this resistance are not well defined. Recent data demonstrate that at least 40% of HER2+ breast cancers have activating mutations in the PI3-kinase gene (PIK3CA) or other alterations in the PI3K pathway. Furthermore, preclinical and clinical investigations, including our own, have implicated these PI3K pathway alterations as potential mediators of resistance to anti-HER2 therapy and have demonstrated that combining PI3K inhibitors with anti-HER2 agents can overcome this resistance. In Project 2, we aim to optimize the application of PI3K-directed therapies, both in novel genetically-engineered mouse (GEM) models and subsequently in a clinical trial. Since a combination of anti-HER2 therapy and PI3K inhibition will likely be ineffective for some patients due to additional mutations bypassing the HER2/PI3K pathway, we will utilize recently developed methods to study mechanisms of resistance that lie outside the PI3K pathway. The aims of this project are to identify and overcome both PI3K-dependent and -independent mechanisms of resistance to targeted therapy of HER2+ breast cancer. Specifically we will: 1) Use GEM models to optimize PI3K-targeted treatment strategies for each subset of HER2+ breast cancer, with an emphasis on comparing pan-PI3K inhibitors with isoform specific agents, 2) Identify novel resistance mechanisms to HER2- and PI3K-targeted therapies in GEM models, and 3) Evaluate the role of PI3K inhibition in conjunction with HER2-targeted therapy in a preoperative clinical trial of patients with HER2+ breast cancer. Tumor tissue from that trial and others will be analyzed with next generation sequencing techniques in order to validate resistance mechanisms identified in Aim 2. Together these studies will strengthen our ability to overcome therapeutic resistance in HER2+ breast cancer and thereby improve outcomes for patients with this disease.

View original record on NIH RePORTER →